Want answers fast?
Text us at (407)233-4006
Text Us Now!
Locations
Facebook Instagram
(407) 233-4006
Facebook Instagram
Peptide Therapy  /  AOD-9604

AOD-9604

A modified fragment of human growth hormone studied for its effects on fat metabolism. AOD-9604 works through a non-hormonal mechanism, targeting adipose tissue without affecting blood sugar, IGF-1, or other hormone levels.

ClassificationModified GH Fragment
Sequence Length16 Amino Acids
Primary InterestFat Metabolism & Body Composition
Research StatusClinical Development
Interested in AOD-9604?

Talk with an Aspire clinician about whether AOD-9604 may be appropriate for your health goals.

Text Us Now
(407) 233-4006
What is AOD-9604?

Advanced Obesity Drug Fragment

AOD-9604 is a synthetic peptide consisting of 16 amino acids, corresponding to a modified fragment (amino acids 177-191) of human growth hormone. It was originally developed to isolate the fat-reducing effects of growth hormone without the growth-promoting or diabetogenic properties.

In preclinical and early clinical research, AOD-9604 has been studied for its effects on fat metabolism, specifically its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) in adipose tissue. Unlike full-length growth hormone, it does not appear to affect blood sugar levels, IGF-1 concentrations, or other hormonal markers.

AOD-9604 is available through licensed compounding pharmacies as an injectable formulation. At Aspire, all AOD-9604 therapies are compounded through licensed U.S. 503A pharmacies and prescribed under clinician supervision.

Image Placeholder
How It Works

Proposed Mechanism of Action

1
Peptide Administration
AOD-9604 is administered via subcutaneous injection
2
Adipose Targeting
Interacts with fat cells through a non-hormonal pathway distinct from GH
3
Metabolic Signaling
Stimulates lipolysis and inhibits lipogenesis in adipose tissue
4
Body Composition
Supports fat reduction without impacting hormones, blood sugar, or IGF-1

AOD-9604 is believed to work by mimicking the lipolytic (fat-burning) region of growth hormone without activating the growth-promoting IGF-1 pathway. This targeted mechanism allows it to influence fat metabolism through a distinct signaling route.

Research suggests it enhances the breakdown of stored triglycerides in adipose tissue while simultaneously reducing the formation of new fat. Importantly, studies have not shown significant effects on blood glucose, insulin sensitivity, or growth hormone-related markers, distinguishing it from full-length GH therapy.

Areas of Interest

What AOD-9604 Is Being Explored For

These are the primary areas where AOD-9604 has been studied or discussed in the context of peptide therapy. Research depth varies by area.

Stubborn Fat Reduction
The primary area of research. AOD-9604 has been studied for its ability to target adipose tissue and support the reduction of stubborn body fat that has not responded to diet and exercise alone.
Metabolic Support
Research has explored AOD-9604's potential to support healthier metabolic function, including improved lipid profiles and metabolic efficiency, without the hormonal side effects of growth hormone.
Body Composition
Patients interested in improving body composition - specifically reducing fat mass while preserving lean tissue - often explore AOD-9604 as part of a broader treatment strategy.
Joint & Cartilage Research
Emerging preclinical research has also investigated AOD-9604's potential effects on cartilage repair and joint health, though this area remains early in development.
Available at Aspire

How AOD-9604 Is Offered

AOD-9604 is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.

Injectable (Subcutaneous)
Questions About AOD-9604?

Text our team anytime during business hours.
Monday through Friday, 9:30 AM - 6:00 PM.
We're here to help you understand your options.

Text Us Now — (407) 233-4006
The Aspire Approach

How Treatment Works

Peptide therapy at Aspire follows a clinician-guided process. AOD-9604 is not available for self-prescribing or anonymous purchase.

1
Conversation
Text or call Aspire. Discuss your goals and whether AOD-9604 therapy may be relevant.
2
Evaluation
Clinical assessment including medical history, current medications, and body composition analysis.
3
Treatment
If appropriate, your clinician prescribes AOD-9604 compounded through a licensed 503A pharmacy.
4
Monitoring
Ongoing follow-up to track progress, adjust protocols, and ensure treatment remains appropriate.
Related Compounds

Often Explored Alongside AOD-9604

These compounds are frequently discussed in similar clinical contexts or combined in treatment protocols.

MOTS-c
Mitochondrial-derived peptide studied for metabolic optimization, AMPK activation, and exercise capacity. A complementary approach to metabolic health.
Learn More →
5-Amino-1MQ
Oral compound targeting NNMT enzyme activity in fat cells. Often discussed alongside AOD-9604 for metabolic and body composition goals.
Learn More →
Tesofensine
Triple reuptake inhibitor studied for appetite suppression and weight management. Addresses the appetite side of body composition.
Learn More →
Frequently Asked Questions

AOD-9604 FAQ

AOD-9604 is most commonly discussed in the context of fat reduction and body composition improvement. Patients typically explore it when stubborn fat has not responded adequately to diet and exercise. Your clinician will evaluate whether it's appropriate for your situation.
No. AOD-9604 is a small fragment of the growth hormone molecule, specifically modified to isolate the fat-metabolizing properties without the growth-promoting or hormonal effects of full-length HGH. It does not raise IGF-1 or affect blood sugar levels.
Research to date suggests AOD-9604 does not significantly affect growth hormone levels, IGF-1, insulin, or blood glucose. This non-hormonal mechanism is one of its distinguishing characteristics.
Response timelines vary by individual. Some patients report changes in body composition within 4-8 weeks, while others may require a longer treatment period. Your clinician will help set realistic expectations.
Commonly reported side effects include mild injection-site reactions. Because it does not affect hormone levels, the side effect profile appears more limited than full-length growth hormone therapy. Your clinician will discuss potential risks during evaluation.
Yes, AOD-9604 is often considered alongside other metabolic compounds, hormone optimization, or weight management programs. Your clinician evaluates the complete treatment picture for compatibility and safety.
AOD-9604 is not an FDA-approved drug. It received GRAS status as a food substance. As a therapeutic compound, it is compounded through licensed 503A pharmacies pursuant to individual prescriptions.
Text Aspire at (407) 233-4006 to start a conversation. Our team will discuss your goals, answer your questions, and guide you through the clinical evaluation process.

AOD-9604 has been studied in both preclinical and early clinical settings, including Phase 2 human trials for obesity. It received GRAS (Generally Recognized as Safe) status from the FDA for use as a food substance. Clinical evidence for injectable therapeutic use continues to develop.

Ready to explore AOD-9604?

Talk with an Aspire clinician about your goals and whether AOD-9604 therapy may be appropriate for you.

Text Us Now
(407) 233-4006  ·  8014 Via Dellagio Way #104, Orlando, FL 32819
ASPIRE CLINIC LOCATIONS
ORLANDO
PITTSBURGH
CLEVELAND

Coming Soon

DALLAS
DUBAI

Coming Soon

Speak With Our Experts

  • (407) 233-4006
  • 8014 Via Dellagio Way, Suite #104 Orlando, FL 32819